Endometriosis is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Endometriosis have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Endometriosis compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Endometriosis overview
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility, and abnormal bleeding. Risk factors include age, uterine abnormalities, history of pelvic infection, and family history. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs), birth control pills, and progestins.
For a complete picture of PTSR and LoA scores for drugs in Endometriosis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.